Trial Profile

A Phase II/III Adaptive Study to Evaluate Efficacy of Centi-B9 in Several Patient Populations Including Hospitalized COVID-19 Patients, Pre-Hospitalized COVID-19 Cases, Post-Exposure Prophylaxis and Pre-Exposure Prophylaxis

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jun 2021 New trial record
02 Jun 2021 According to a Centivax media release, the company is currently open to partnership for this Phase II/III portion of the trial, commercial manufacturing or global distribution of Centi-B9.
02 Jun 2021 According to a Centivax media release, Centivax will seek Emergency Use Authorization during interim analysis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com